home > drugs a-z list > erbitux (cetuximab) drug center

Erbitux Drug Center

Erbitux (cetuximab), in combination with radiation therapy, is a monoclonal antibody indicated for the initial treatment of locally or regionally advanced head and neck cancer of a specific type (squamous cell carcinoma). Used alone Erbitux is also approved to treat patients with head and neck cancers that have returned in the same location or spread to other parts of the body and for head and neck cancers that have progressed following platinum-based chemotherapy. It is also used on metastatic colorectal cancers that contain epidermal growth factor receptors. The drug is not available in generic form. The most common side effects reported in patients receiving cetuximab were rash, itching (pruritus), nail changes, headache, diarrhea, and respiratory, skin, and mouth infections. Erbitux also can cause low serum magnesium, potassium, and calcium. Erbitux has been associated with serious and potentially life-threatening infusion reactions and heart attack. Patients taking Erbitux should limit their exposure to the sun.

Erbitux is supplied at a concentration of 2 mg/mL in 100 mg (50 mL) or 200 mg (100 mL), single-use vials. Erbitux IV dosage and administration should only be done by those trained in the administration of this drug. Serious side effects include a low percentage of patients that experience severe side effects of life-threatening allergic reactions and heart attacks, especially if the patient was also obtaining chemotherapy or radiotherapy. These serious reactions most often occur at the time of the first IV infusion, so infusion instructions must be carefully followed by trained personnel in an appropriate setting (hospital or special facility) . Erbitux may be passed form the mother and cause harm to the fetus. Both males and females must use contraception during Erbitux therapy, and for six months after the last dose of Erbitux. Erbitux should only be used during pregnancy if the potential benefit is greater than the potential risk to the fetus. Because Erbitux may be passed through breast milk, nursing is not recommended during Erbitux therapy and for two months following the last dose of Erbitux. Safety and effectiveness of Erbitux has not been determined for pediatric patients.

Our Erbitux Drug Center provides a comprehensive view of available drug information as well as related drugs, user reviews, supplements, and diseases, and condition.